#United States #New York #Prostate Cancer #Actinium Pharmaceuticals #ATNM-400

Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400

Actinium Pharmaceuticals, a trailblazer in targeted radiotherapeutics, is organizing a webinar on December 1, 2026, at 8:00 AM ET to shed light on the revolutionary treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) through their innovative therapy, ATNM-400. The webinar will feature insights from Dr. Michael J. Morris, a leading expert from Memorial Sloan Kettering Cancer Center, along with members of Actinium's management team.

This event is pivotal for anyone interested in understanding the advances in spearheading new treatments for prostate cancer, particularly in cases where traditional therapies have seen limited success. The main focus will be the first-in-class HER3-targeted alpha radiotherapy, ATNM-400, amidst a backdrop of increasing unmet needs in the mCRPC sphere.

The Expertise of Dr. Michael J. Morris

Dr. Morris specializes in developing targeted radiopharmaceuticals for prostate cancer and is highly recognized for his contributions to clinical trials, particularly the groundbreaking Phase 3 VISION trial. His extensive knowledge will help guide the conversation as he delves into the implications of the therapy and its potential effectiveness across mCRPC populations, particularly those expressing low or no PSMA.

Unpacking ATNM-400

ATNM-400 is an investigational radioconjugate that artfully combines the HER3-targeting monoclonal antibody barecetamab with Actinium-225, an alpha-emitting isotope. This unique formulation aims to enhance therapeutic efficacy through prolonged tumor localization while minimizing toxicities that are prevalent in standard treatments. Throughout the webinar, findings from the ongoing Phase 1 HERACT-PRO-1 trial will be discussed, showcasing promising characteristics, including significant tumor uptake and retention observed in initial studies.

Key topics will include:

• - The rationale behind targeting HER3 in therapeutic design.
• - Real-world applicability amongst diverse patient populations.
• - Recent data from ATNM-400's clinical trial results, including a discussion on the RADIANZ imaging study which aims to validate the drug's applicability across tumor types beyond just prostate cancer.

Engaging with the Community

The webinar will offer a unique live Q&A session, allowing participants to interact directly with Dr. Morris and the Actinium team, facilitating a discussion that extends beyond presentation content into practical and clinical inquiries.

Participants are encouraged to register for the webinar ahead of time through Actinium's official portal. Registration ensures that the audience can stay informed about the advancements and therapeutic strategies being developed by Actinium in the rapidly evolving realm of cancer care.

Actinium’s Vision for Targeted Radiotherapies

Actinium Pharmaceuticals has made significant strides in the domain of radiotherapies with an aim to improve outcomes for cancer patients. Their portfolio is illustrative of their innovative approach, which includes a special focus on therapeutic agents designed for solid tumors and hematologic malignancies.

As they progress with ATNM-400, Actinium adheres to a biology-led strategy, pinpointing specific antigens that underscore the mechanisms of cancer cell survival and growth. This not only emphasizes their commitment to treating prostate cancer but also points toward broader application possibilities in various solid tumors, including lung, breast, colorectal, and ovarian cancers.

In summary, the upcoming webinar represents a noteworthy opportunity to understand the challenges and developments within mCRPC treatment. It establishes Actinium's ongoing mission while encouraging community involvement in discussions about future therapies.

For more information and registration details, visit Actinium's official website at www.actiniumpharma.com.